CINELINE MOVIE MAX

**Date: 30 July 2026**

To,
Manager – Listing Department,

| **BSE Limited** | **National Stock Exchange of India Limited** |
|---|---|
| 1st Floor, New Trading Ring,<br>PJ Towers, Dalal Street, Fort, Mumbai - 400 001 | Exchange Plaza, Plot No. C-1, G Block, Bandra Kurla Complex,<br>Bandra East, Mumbai – 400 051 |

**Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("Listing Regulations").**

**Ref: Allotment of 38,46,153 Equity Shares pursuant to conversion of warrants allotted on preferential basis.**

**Company Code: 532807 (BSE) / CINELINE (NSE)**

Dear Sir / Madam,

This is in furtherance to the intimations given by the Company on 3rd February 2025 with respect to allotment of 38,46,153 warrants convertible into equity shares having face value ₹**5** (Indian Rupees Five Only) each fully paid-up. The issue price of the warrant ₹**117** (Indian Rupees One Hundred Seventeen Only) which includes ₹29.25 per warrant ("Warrant Subscription Price") and the warrant exercise price at the rate of ₹87.75 per warrant ("Warrant Exercise Price").

Pursuant to Regulation 30 of Listing Regulations, the Company is making the following disclosures:

1. The Company has received ₹**33,74,99,925.75**/- (Indian Rupees Thirty-three Crore Seventy-four Lakhs Ninety-Nine thousand Nine Hundred Twenty-Five and Seventy-Five Paisa Only) warrant exercise price @₹87.75 per warrant for allotment of 38,46,153 equity shares upon conversion of 38,46,153 warrants.

2. Upon receipt of aforesaid amount, as per the terms of the issue of warrants, the Board of Directors, has on today 30 July 2026, allotted 38,46,153 equity shares having face value of ₹5/- each pursuant to conversion of warrants. The details are given in '**Annexure – A**'

Consequently, the issued and paid up share capital of the Company stands increased to ₹19,05,62,935/- consisting of 3,81,12,587 equity shares of ₹5/- each. The new equity shares so allotted, shall rank pari-passu with the existing equity shares of the Company.

Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI circular dated July 13, 2023, bearing reference no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 ("SEBI Circular'), are provided in **'Annexure B'.**

Kindly take the same on your records.

**For Cineline India Limited**

RASESH BABUBHAI KANAKIA

Digitally signed by RASESH BABUBHAI KANAKIA
Date: 2026.07.30 17:40:49 +05'30'

**Rasesh Kanakia**
**Chairman & Whole Time Director**
**DIN: 00015857**

**Encl.:** As above

**Annexure A**

**List of Allottees**

| Sr No. | Name of the Warrants Allottee(s) | Total Number of Warrants held | Number of Warrants applied for conversion | Warrant exercise price (Received @ ₹87.75 per warrant) (Amount in ₹) | Number of equity shares allotted upon conversion / exchange of Warrants |
|---|---|---|---|---|---|
| | **Promoter / Promoter Group** | | | | |
| 1. | Ashish Rasesh Kanakia | 5,34,188 | 5,34,188 | 4,68,74,997 | 5,34,188 |
| 2. | Niyati Rasesh Kanakia | 5,34,188 | 5,34,188 | 4,68,74,997 | 5,34,188 |
| 3. | Vrutant Himanshu Kanakia | 5,34,188 | 5,34,188 | 4,68,74,997 | 5,34,188 |
| 4. | Vrusti Benefit Trust | 5,34,188 | 5,34,188 | 4,68,74,997 | 5,34,188 |
| | **Non-Promoter** | | | | |
| 5. | Utpal Sheth | 17,09,401 | 17,09,401 | 14,99,99,937.75 | 17,09,401 |
| | | | **TOTAL** | **33,74,99,925.75** | **38,46,153** |

**Annexure B**

The details as required under Regulation 30 of SEBI Listing Regulations read with SEBI Circular dated July 13, 2023 are as under:

<table>
<tr><th>Sr No.</th><th>Particulars</th><th>Description</th></tr>
<tr><td>1</td><td>Type of Securities issue</td><td>Equity Shares pursuant to exercise of option of conversion of warrants.</td></tr>
<tr><td>2</td><td>Type of issuance</td><td>Preferential allotment</td></tr>
<tr><td>3</td><td>Total number of securities issued or the total amount for which the securities issued (approximately)</td><td>Allotment of 38,46,153 Equity Shares of face value of ₹5/- each upon conversion/ exchange of/ for equal number of Warrants at an issue price of ₹117 each upon receipt of balance amount at the rate of ₹87.75 per warrant (being 75% of the issue price per warrant as "Warrant Exercise Price") aggregating to ₹33,74,99,925.75/-</td></tr>
<tr><td colspan="3">Additional information in case of preferential issue:</td></tr>
<tr><td>4</td><td>Name of the allottee</td><td>As per Annexure A</td></tr>
<tr><td>5</td><td>Post allotment of securities – Outcome of the subscription, Issue price / allotted price (in case of convertibles)</td><td>
<table>
<tr><th rowspan="2">Investor</th><th colspan="2">Pre-Issue shareholding</th><th rowspan="2">No. of shares allotted upon conversion of warrant</th><th colspan="2">Post-Issue shareholding</th></tr>
<tr><th>Nos of Shares</th><th>%</th><th>Nos of Shares</th><th>%</th></tr>
<tr><td>Ashish Rasesh Kanakia</td><td>10,42,133</td><td>3.04</td><td>5,34,188</td><td>15,76,321</td><td>4.14</td></tr>
<tr><td>Niyati Rasesh Kanakia</td><td>10,42,133</td><td>3.04</td><td>5,34,188</td><td>15,76,321</td><td>4.14</td></tr>
<tr><td>Vrutant Himanshu Kanakia</td><td>10,42,133</td><td>3.04</td><td>5,34,188</td><td>15,76,321</td><td>4.14</td></tr>
<tr><td>Vrusti Benefit Trust</td><td>10,42,133</td><td>3.04</td><td>5,34,188</td><td>15,76,321</td><td>4.14</td></tr>
<tr><td>Utpal Sheth</td><td>Nil</td><td>Nil</td><td>17,09,401</td><td>17,09,401</td><td>4.49</td></tr>
</table>
<br>Allotted 38,46,153 Equity Shares upon receipt of Warrant Exercise Price of ₹87.75 per warrant (being 75% of the issue price per warrant as "Warrant Exercise Price").<br><br>No. of investors: 5 (Five)<br><br>Post conversion issued, subscribed and paid-up share capital of the Company is ₹19,05,62,935/- consisting of 3,81,12,587 equity shares of ₹5/- each fully Paid-up.</td></tr>
<tr><td>6</td><td>In case of convertibles — intimation on conversion of securities or on lapse</td><td>Intimation on conversion of securities:<br><br>Conversion option has been exercised by allottee as mentioned in Annexure – A.</td></tr>
</table>

| Sr No. | Particulars | Description |
|---|---|---|
| | of the tenure of the instrument; | An amount equivalent to 25% of the warrant issue price has been received at the time of subscription and allotment of each Warrant on 3rd February 2025 and the balance 75% amount of the warrant issue price shall be received at the time of exercise of option of conversion of warrants into equity shares by allottee to whom the warrants have been allotted.<br><br>The tenure of the warrants shall not exceed 18 (eighteen) months from the date of allotment. Each warrant shall carry a right to subscribe 1 (one) Equity Share per warrant, which may be exercised in one or more tranches during the period commencing from the date of allotment of warrants until the expiry of 18(eighteen) months from the date of allotment of the warrants.<br><br>In the event that, a warrant holder does not exercise the warrants within a period of 18 (Eighteen) months from the date of allotment of such warrants, the unexercised warrants shall lapse and the amount paid by the warrant holders on such Warrants shall stand forfeited by the Company. |